Oncology Peer Review On-The-Go: COVID-19, Cancer, and the Potential of mRNA Vaccines

Podcast

Mehmet Sitki Copur, MD, discussed his article in the Journal ONCOLOGY® focusing on COVID-19, messenger RNA vaccines, and the excitement surrounding its integration into the future of cancer treatment.

This episode of the “Oncology Peer Review On-The-Go” podcast centers around an article publishing in the April issue of the Journal ONCOLOGY®, titled “Messenger RNA Vaccines-Beckoning of a New Era in Cancer Immunotherapy.” The article touches on the recent development of mRNA vaccines approved to combat COVID-19 and how this offers optimism for the future of mRNA to treat patients with cancer.

The author, Mehmet Sitki Copur, MD, of the University of Nebraska Medical Center, broke down the basics of mRNA, its history, challenges, and potential opportunities around this relatively new class of vaccine.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Related Videos
coronavirus
Related Content
Long-term circulating tumor DNA responses appear to align with progression-free survival trends in a phase 2/3 trial of the GRANITE vaccine in those with microsatellite-stable colorectal cancer.

Personalized Vaccine Yields Early PFS Benefit in Metastatic MSS-CRC

April 2nd 2024
Article

Long-term circulating tumor DNA responses appear to align with progression-free survival trends in a phase 2/3 trial of the GRANITE vaccine in those with microsatellite-stable colorectal cancer.

Oncology Peer Review On-The-Go

Oncology Peer Review On-The-Go: Clinical Trials System and the COVID-19 Pandemic

August 3rd 2020
Podcast

CancerNetwork’s latest episode of the “Oncology Peer Review On-The-Go” podcast examines an article in the July issue of the journal ONCOLOGY on clinical trials during the COVID-19 pandemic.

COVID-19 Vaccination in Patients With Cancer and Recipients of Cellular Therapy

COVID-19 Vaccination in Patients With Cancer and Recipients of Cellular Therapy

March 2nd 2023
Article

Fareed Khawaja, MBBS, and colleagues provide a comprehensive overview of COVID-19 vaccine efficacy and safety among patients with cancer in the United States.

Those immunized between the ages of 12 and 13 in England experienced a significant estimated reduction in cervical cancer and grade 3 cervical intraepithelial neoplasia incidence rates compared with unvaccinated women.

Cervical Cancer and Grade 3 Cervical Intraepithelial Neoplasia Incidence Reduced in Young, HPV-Vaccinated Individuals

November 4th 2021
Article

Those immunized between the ages of 12 and 13 in England experienced a significant estimated reduction in cervical cancer and grade 3 cervical intraepithelial neoplasia incidence rates compared with unvaccinated women.

UV1 Cancer Vaccine Receives FDA Fast Track Designation in Melanoma

UV1 Cancer Vaccine Receives FDA Fast Track Designation in Melanoma

November 3rd 2021
Article

UV1 has received fast track designation from the FDA for the use in unresectable or metastatic melanoma.

A 64-Year-Old Man With Germline BRCA2-Mutated Breast Cancer: Known and Unknown Aspects of Male Breast Cancer

A 64-Year-Old Man With Germline BRCA2-Mutated Breast Cancer: Known and Unknown Aspects of Male Breast Cancer

August 13th 2021
Article

This study presents a male breast cancer case with a germline BRCA2 mutation and discusses the epidemiologic, pathologic, and clinical characteristics along with treatment and follow-up recommendations in view of our recent understanding of the disease.